As hype around new treatments for the blood disorder hyperkalemia continues unabated after AstraZeneca's $2.7 billion buyout of ZS Pharma last year, Relypsa ($RLYP ...

What:Relypsa (NASDAQ: RLYP) , a biopharmaceutical company developing gastrointestinal medicines, saw its shares surge 58% higher at the opening bell today on the news that the Swiss-based Galenica ...

SOURCE: FLICKR USER STEVE JURVETSON. What:Swirling rumors that an acquirer might step up to buy the company caused shares inRelypsa, to soar 67.6% higher today. So what: The company has been the ...

Relypsa, Inc. 's RLYP lead candidate, Veltassa gained approval in the U.S. for the treatment of hyperkalemia. Shares which should have been up with the positive news were, however, down 27.2% due to ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million.

Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept ...

Relypsa, Inc. today announced an $80 million Series C preferred stock financing, including participation from both new and existing investors. Proceeds will be used to fund late-stage development, ...

What: Shares of Relypsa (RLYP +0.00%) exploded more than 30% higher as of 3:30 p.m. today after a rumor broke that Merck (MRK +1.85%) has plans to make an offer to buy out the company. So what: ...

The U.S. Food and Drug Administration approved Relypsa Inc's drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is ...

Wednesday put continued pressure on the stock market, and investors appeared to focus on ongoing pressure in the energy sector and fears about global macroeconomic conditions in pushing major market ...